Basic Information
Yargesa
Regulatory Information
EMEA/H/C/004016
March 22, 2017
January 26, 2017
5
February 29, 2024
Company Information
netehrlands
Rouboslaan 32 2252 TR Voorschoten
Piramal Critical Care BV
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease. Yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Yargesa. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Yargesa. For practical information about using Yargesa, patients should read the package leaflet or contact their doctor or pharmacist.